PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis | Dr Ruben Mesa at Annual Meeting 2015 - 101271

Spotlight
Video

PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis | Dr Ruben Mesa at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 07/22/15
Added : 3 years ago



Recommended

Nothing found.

More From EMJ

Nothing found.